Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action

HR Wardill, ST Sonis, NMA Blijlevens… - Supportive Care in …, 2020 - Springer
Purpose Despite advances in personalizing the efficacy of cancer therapy, our ability to
identify patients at risk of severe treatment side effects and provide individualized supportive …

Methodological approaches for assessing certainty of the evidence in umbrella reviews: A scoping review

S Sadoyu, KA Tanni, N Punrum, S Paengtrai… - PloS one, 2022 - journals.plos.org
Introduction The number of umbrella reviews (URs) that compiled systematic reviews and
meta-analysis (SR-MAs) has increased dramatically over recent years. No formal guidance …

Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

JM Campbell, E Bateman, MD Stephenson… - Cancer chemotherapy …, 2016 - Springer
Purpose Methotrexate chemotherapy is associated with various toxicities which can result in
the interruption or discontinuation of treatment and a subsequently raised risk of relapse …

Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy

ZN Al-Mahayri, GP Patrinos, BR Ali - Frontiers in pharmacology, 2020 - frontiersin.org
Breast cancer (BC) is one of the most prevalent types of cancer worldwide with high
morbidity and mortality rates. Treatment modalities include systemic therapy, in which …

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

JM Campbell, MD Stephenson, E Bateman… - The …, 2017 - nature.com
Irinotecan chemotherapy toxicities can be severe, and may result in treatment delay,
morbidity and in some rare cases death. This systematic review of systematic reviews …

Anticancer diiron vinyliminium complexes: a structure–activity relationship study

S Braccini, G Rizzi, L Biancalana, A Pratesi, S Zacchini… - Pharmaceutics, 2021 - mdpi.com
A series of 16 novel diiron complexes of general formula [Fe2Cp2 (CO)(μ-CO){μ-η1: η3-C
(R′) C (R ″) CN (R)(Y)}] CF3SO3 (2–7), bearing different substituents on the bridging …

Extracellular vesicles: A novel tool facilitating personalized medicine and pharmacogenomics in oncology

K Goričar, V Dolžan, M Lenassi - Frontiers in pharmacology, 2021 - frontiersin.org
Biomarkers that can guide cancer therapy based on patients' individual cancer molecular
signature can enable a more effective treatment with fewer adverse events. Data on …

[HTML][HTML] SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand

R Palmirotta, C Carella, E Silvestris, M Cives… - Oncotarget, 2018 - ncbi.nlm.nih.gov
In the “precision medicine” era, chemotherapy still remains the backbone for the treatment of
many cancers, but no affordable predictors of response to the chemodrugs are available in …

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

A Maslarinou, VG Manolopoulos… - Frontiers in Pharmacology, 2023 - frontiersin.org
Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various
solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs …

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

E Cecchin, E De Mattia, F Ecca, G Toffoli - Drug Resistance Updates, 2018 - Elsevier
Adverse events affect the pharmacological treatment of approximately 90% of colorectal
cancer (CRC) patients at any stage of the disease. Chemotherapy including …